Fat Grafting With Expanded Adipose-Derived Stromal Cells for Breast Augmentation: A Randomized Controlled Trial.

Autor:	Vester-Glowinski PV; Department of Plastic Surgery and Burns, Copenhagen University Hospital, Copenhagen, Denmark., Herly M; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark., Ørholt M; Department of Plastic Surgery and Burns, Copenhagen University Hospital, Copenhagen, Denmark., Rasmussen BS; AK Nygart Private Hospital, København, Denmark., Müller FC; Department of Radiology, Herlev and Gentofte Hospital, Herlev, Denmark., Elberg JJ; private practice in Copenhagen, Denmark., Thomsen C; Department of Radiology, Zealand University Hospital, Roskilde, Denmark., Drzewiecki KT; Department of Plastic Surgery and Burns, Copenhagen University Hospital, Copenhagen, Denmark.
Jazyk:	angličtina
Zdroj:	Aesthetic surgery journal [Aesthet Surg J] 2022 Oct 13; Vol. 42 (11), pp. 1279-1289.
DOI:	10.1093/asj/sjac159
Abstrakt:	Background: The main challenge with fat grafting is loss of some of the graft to postsurgery resorption. Previous studies suggest that adipose-derived stromal cells (ASCs) can improve the volume retention of fat grafts but there is a lack of randomized trials to support the use of ASCs in clinical practice. Objectives: This trial aimed to investigate whether ASCs improve fat graft volume retention in patients undergoing breast augmentation with lipofilling. Methods: This was a double-blind, randomized controlled trial of breast augmentation with ASC-enriched fat grafting. Healthy women aged 30 to 45 years were enrolled. First, the participants underwent liposuction to obtain fat for culture expansion of ASCs. Then, the participants were randomly assigned to undergo a 300- to 350-mL breast augmentation with ASC-enriched fat grafting (10 × 106 ASCs/mL fat graft) to 1 of their breasts and placebo-enriched fat grafting of identical volume to the contralateral breast. The primary outcome was fat graft volume retention after a 1-year follow-up measured with MRI. The trial is registered at www.clinicaltrialsregister.eu (EudraCT-2014-000510-59). Results: Ten participants were included in the trial; all completed the treatment and follow-up. No serious adverse events occurred. Fat graft volume retention after 1 year was 54.0% (95% CI, 30.4%-77.6%) in the breasts treated with ASC-enriched fat grafting (n = 10) and 55.9% (95% CI, 28.9%-82.9%) in the contralateral breasts treated with placebo-enriched fat grafting (n = 10) (P = 0.566). Conclusions: The findings of this trial do not support that ASC-enriched fat grafting is superior to standard fat grafting for breast augmentation. (© The Author(s) 2022. Published by Oxford University Press on behalf of The Aesthetic Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu